1
|
Sahraei M, Chaube B, Liu Y, Sun J, Kaplan A, Price NL, Ding W, Oyaghire S, García-Milian R, Mehta S, Reshetnyak YK, Bahal R, Fiorina P, Glazer PM, Rimm DL, Fernández-Hernando C, Suárez Y. Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. J Clin Invest 2020; 129:5518-5536. [PMID: 31710308 PMCID: PMC6877327 DOI: 10.1172/jci127125] [Citation(s) in RCA: 85] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Accepted: 09/10/2019] [Indexed: 02/06/2023] Open
Abstract
microRNA-21 (miR-21) is the most commonly upregulated miRNA in solid tumors. This cancer-associated microRNA (oncomiR) regulates various downstream effectors associated with tumor pathogenesis during all stages of carcinogenesis. In this study, we analyzed the function of miR-21 in noncancer cells of the tumor microenvironment to further evaluate its contribution to tumor progression. We report that the expression of miR-21 in cells of the tumor immune infiltrate, and in particular in macrophages, was responsible for promoting tumor growth. Absence of miR-21 expression in tumor- associated macrophages (TAMs), caused a global rewiring of their transcriptional regulatory network that was skewed toward a proinflammatory angiostatic phenotype. This promoted an antitumoral immune response characterized by a macrophage-mediated improvement of cytotoxic T-cell responses through the induction of cytokines and chemokines, including IL-12 and C-X-C motif chemokine 10. These effects translated to a reduction in tumor neovascularization and an induction of tumor cell death that led to decreased tumor growth. Additionally, using the carrier peptide pH (low) insertion peptide, we were able to target miR-21 in TAMs, which decreased tumor growth even under conditions where miR-21 expression was deficient in cancer cells. Consequently, miR-21 inhibition in TAMs induced an angiostatic and immunostimulatory activation with potential therapeutic implications.
Collapse
Affiliation(s)
- Mahnaz Sahraei
- Department of Comparative Medicine.,Program in Integrative Cell Signaling and Neurobiology of Metabolism (ICSNM).,Vascular Biology and Therapeutics Program (VBT).,Department of Pathology
| | - Balkrishna Chaube
- Department of Comparative Medicine.,Program in Integrative Cell Signaling and Neurobiology of Metabolism (ICSNM).,Vascular Biology and Therapeutics Program (VBT).,Department of Pathology
| | | | - Jonathan Sun
- Department of Comparative Medicine.,Program in Integrative Cell Signaling and Neurobiology of Metabolism (ICSNM).,Vascular Biology and Therapeutics Program (VBT).,Department of Pathology
| | | | - Nathan L Price
- Department of Comparative Medicine.,Program in Integrative Cell Signaling and Neurobiology of Metabolism (ICSNM).,Vascular Biology and Therapeutics Program (VBT).,Department of Pathology
| | - Wen Ding
- Department of Comparative Medicine.,Program in Integrative Cell Signaling and Neurobiology of Metabolism (ICSNM).,Vascular Biology and Therapeutics Program (VBT).,Department of Pathology
| | | | | | - Sameet Mehta
- Yale Center for Genome Analysis, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Yana K Reshetnyak
- Physics Department, University of Rhode Island, Kingston, Rhode Island, USA
| | - Raman Bahal
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut, USA
| | - Paolo Fiorina
- Division of Nephrology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | | | | | - Carlos Fernández-Hernando
- Department of Comparative Medicine.,Program in Integrative Cell Signaling and Neurobiology of Metabolism (ICSNM).,Vascular Biology and Therapeutics Program (VBT).,Department of Pathology
| | - Yajaira Suárez
- Department of Comparative Medicine.,Program in Integrative Cell Signaling and Neurobiology of Metabolism (ICSNM).,Vascular Biology and Therapeutics Program (VBT).,Department of Pathology
| |
Collapse
|
2
|
Liu M, Tang X, Ding J, Liu M, Zhao B, Deng Y, Song Y. A Sialylated-Bortezomib Prodrug Strategy Based on a Highly Expressed Selectin Target for the Treatment of Leukemia or Solid Tumors. Pharm Res 2019; 36:176. [PMID: 31686241 DOI: 10.1007/s11095-019-2714-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Accepted: 10/04/2019] [Indexed: 02/07/2023]
Abstract
PURPOSE This study aimed to explore the potential of sialic acid - related selectin targeting strategy in the treatment of leukemia and some solid tumors. We expected it could "actively" bind tumor cells and kill them, reducing non-specific toxicity to normal cells. METHODS BOR-SA prodrug was synthesized by reacting an ortho-dihydroxy group in SA with a boronic acid group in BOR. Two kinds of leukemia cells (RAW264.7 and HL60 cells), one solid sarcoma cell model (S180 cells) and their corresponding normal cells (monocytes (MO), neutrophil (NE) and fibroblast (L929)) were selected for the in vitro cell experiments (cytotoxicity, cellular uptake, cell cycle and apoptosis experiments). The S180 tumor-bearing Kunming mice model was established for anti-tumor pharmacodynamic experiments. RESULTS In vitro cell assay results showed that uptake of BOR-SA by HL60 and S180 cells were increased compared with the control group. BOR-SA induced a lower IC50, higher ratio of apoptosis and cell cycle arrest of tumor cells. In vivo anti-S180 tumor pharmacodynamics experiments showed that mice in the BOR-SA group had higher tumor inhibition rate, higher body weight and lower immune organ toxicity compared with the control group. CONCLUSIONS sialic acid-mediated selectin targeting strategy may have great potential in the treatment of related tumors.
Collapse
Affiliation(s)
- Mingqi Liu
- College of Pharmacy, Shenyang Pharmaceutical University, 85 Hongliu Road, Benxi, 117004, Liaoning, China
| | - Xueying Tang
- College of Pharmacy, Shenyang Pharmaceutical University, 85 Hongliu Road, Benxi, 117004, Liaoning, China
| | - Junqiang Ding
- College of Pharmacy, Shenyang Pharmaceutical University, 85 Hongliu Road, Benxi, 117004, Liaoning, China
| | - Mengyang Liu
- College of Pharmacy, Shenyang Pharmaceutical University, 85 Hongliu Road, Benxi, 117004, Liaoning, China
| | - Bowen Zhao
- College of Pharmacy, Shenyang Pharmaceutical University, 85 Hongliu Road, Benxi, 117004, Liaoning, China
| | - Yihui Deng
- College of Pharmacy, Shenyang Pharmaceutical University, 85 Hongliu Road, Benxi, 117004, Liaoning, China
| | - Yanzhi Song
- College of Pharmacy, Shenyang Pharmaceutical University, 85 Hongliu Road, Benxi, 117004, Liaoning, China.
| |
Collapse
|
3
|
Koch J, Hau J, Pravsgaard Christensen J, Elvang Jensen H, Bagge Hansen M, Rieneck K. Immune cells from SR/CR mice induce the regression of established tumors in BALB/c and C57BL/6 mice. PLoS One 2013; 8:e59995. [PMID: 23555858 PMCID: PMC3605416 DOI: 10.1371/journal.pone.0059995] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2012] [Accepted: 02/23/2013] [Indexed: 11/18/2022] Open
Abstract
Few experimental models are available for the study of natural resistance to cancer. One of them is the SR/CR (spontaneous regression/complete resistance) mouse model in which natural resistance to a variety of cancer types appeared to be inherited in SR/CR strains of BALB/c and C57BL/6 mice. The genetic, cellular, and molecular effector mechanisms in this model are largely unknown, but cells from the innate immune system may play a significant role. In contrast to previous observations, the cancer resistance was limited to S180 sarcoma cancer cells. We were unable to confirm previous observations of resistance to EL-4 lymphoma cells and J774A.1 monocyte-macrophage cancer cells. The cancer resistance against S180 sarcoma cells could be transferred to susceptible non-resistant BALB/c mice as well as C57BL/6 mice after depletion of both CD4+/CD8+ leukocytes and B-cells from SR/CR mice. In the responding recipient mice, the cancer disappeared gradually following infiltration of a large number of polymorphonuclear granulocytes and remarkably few lymphocytes in the remaining tumor tissues. This study confirmed that the in vivo growth and spread of cancer cells depend on a complex interplay between the cancer cells and the host organism. Here, hereditary components of the immune system, most likely the innate part, played a crucial role in this interplay and lead to resistance to a single experimental cancer type. The fact that leukocytes depleted of both CD4+/CD8+ and B cells from the cancer resistant donor mice could be transferred to inhibit S180 cancer cell growth in susceptible recipient mice support the vision of an efficient and adverse event free immunotherapy in future selected cancer types.
Collapse
Affiliation(s)
- Janne Koch
- Department of Experimental Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
| | | | | | | | | | | |
Collapse
|
4
|
Koch J, Hau J, Jensen HE, Nielsen CH, Rieneck K. The cellular cancer resistance of the SR/CR mouse. APMIS 2012; 120:974-87. [PMID: 23030360 DOI: 10.1111/j.1600-0463.2012.02925.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2011] [Accepted: 05/01/2012] [Indexed: 12/27/2022]
Abstract
The SR/CR mouse phenotype, first described in 1999 in BALB/c and later bred into C57BL/6 mice, is resistant to cancer formation following high doses of cancer cells administered intraperitoneally. The tumor cell targeting and destruction mechanisms have not been identified. By fluorescence-activated cell sorting analysis, the immune response of SR/CR mice after intraperitoneal injection of cancer cells was investigated and compared with parent strain mice. A massive influx of leukocytes into the peritoneal cavity was found. A large fraction of these leukocytes were polymorphonuclear granulocytes, macrophages and natural killer cells. A relative decrease in influx of B-cells compared with controls was demonstrated. Increased proportions of leukocytes belonging to the innate immune system were also demonstrated in splenocytes of SR/CR mice. Cytospins of peritoneal fluid from SR/CR mice after cancer cell injection showed formations of immune cells morphologically resembling polymorphonuclear granulocytes and macrophages adjoining the cancer cells. The results point to the potential involvement of innate immune cells in cancer immunology. Our data support migration of polymorphonuclear granulocytes, macrophages and NK cells into the peritoneum of the SR/CR mouse in response to intraperitoneal injection of S180 cancer cells. The cell composition of spleens of SR/CR mice reflected the differential regulation of the innate immune cells in peritoneal exudates. Both peritoneal exudates and the spleens of SR/CR mice contained decreased proportions of B-cells compared with BALB/c and C57BL/6 mice. We reproduce important aspects of previous published data and further extend them by showing differentially regulated populations of splenocytes including B-lymphocytes in SR/CR mice compared with parent strain controls. Importantly, this differentially regulated immune response of SR/CR mice could not be found in response to challenge with the lymphoma cell line EL-4.
Collapse
Affiliation(s)
- Janne Koch
- Department of Experimental Medicine, Faculty of Health sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
| | | | | | | | | |
Collapse
|
5
|
Wang Y, Li P, Wang S, Hu J, Chen XA, Wu J, Fisher M, Oshaben K, Zhao N, Gu Y, Wang D, Chen G, Wang Y. Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J Biol Chem 2012; 287:25941-53. [PMID: 22605338 DOI: 10.1074/jbc.m112.375725] [Citation(s) in RCA: 120] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Tumor suppressor genes are frequently silenced in cancer cells by enzymes catalyzing epigenetic histone modifications. The peptidylarginine deiminase family member PAD4 (also called PADI4) is markedly overexpressed in a majority of human cancers, suggesting that PAD4 is a putative target for cancer treatment. Here, we have generated novel PAD inhibitors with low micromolar IC(50) in PAD activity and cancer cell growth inhibition. The lead compound YW3-56 alters the expression of genes controlling the cell cycle and cell death, including SESN2 that encodes an upstream inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway. Guided by the gene expression profile analyses with YW3-56, we found that PAD4 functions as a corepressor of p53 to regulate SESN2 expression by histone citrullination in cancer cells. Consistent with the mTORC1 inhibition by SESN2, the phosphorylation of its substrates including p70S6 kinase (p70S6K) and 4E-BP1 was decreased. Furthermore, macroautophagy is perturbed after YW3-56 treatment in cancer cells. In a mouse xenograft model, YW3-56 demonstrates cancer growth inhibition activity with little if any detectable adverse effect to vital organs, whereas a combination of PAD4 and histone deacetylase inhibitors further decreases tumor growth. Taken together, our work found that PAD4 regulates the mTORC1 signaling pathway and that PAD inhibitors are potential anticancer reagents that activate tumor suppressor gene expression alone or in combination with histone deacetylase inhibitors.
Collapse
Affiliation(s)
- Yuji Wang
- Center for Eukaryotic Gene Regulation, Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Vikis HG, Jackson EN, Krupnick AS, Franklin A, Gelman AE, Chen Q, Piwnica-Worms D, You M. Strain-specific susceptibility for pulmonary metastasis of sarcoma 180 cells in inbred mice. Cancer Res 2010; 70:4859-67. [PMID: 20501835 DOI: 10.1158/0008-5472.can-09-4177] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Most cancer deaths are a result of metastasis. To extend our understanding of the factors that influence the process, we aimed to develop a mouse model of pulmonary metastasis that can be assayed in multiple inbred mouse strains for further use in identification of host genetic variants that influence metastasis. We used i.v. injection of Sarcoma 180 (S180) cells, which can be tracked and quantified by bioluminescence imaging. We observed growth of S180 cells solely in the lung and observed a wide range of pulmonary metastasis among inbred mouse strains. Interestingly, we noted that the BTBRT+tf/J strain exhibited complete clearance and provide evidence that the mechanism of resistance may involve immune factors, as strains subjected to whole-body irradiation are significantly more susceptible to tumor growth. One possible mechanism of resistance to pulmonary metastasis in BTBRT+tf/J mice may require T-cell function. Our experiments present a new mouse model for further characterization of the genetics and mechanisms of pulmonary metastasis.
Collapse
Affiliation(s)
- Haris G Vikis
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Li J, King AV, Stickel SL, Burgin KE, Zhang X, Wagner TE, Wei Y. Whole tumor cell vaccine with irradiated S180 cells as adjuvant. Vaccine 2008; 27:558-64. [PMID: 19027812 DOI: 10.1016/j.vaccine.2008.11.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2008] [Revised: 10/29/2008] [Accepted: 11/03/2008] [Indexed: 11/16/2022]
Abstract
Whole tumor cell vaccines have been widely studied and remain promising cancer immunotherapies. In the present study, we discovered that vaccination with irradiated mouse sarcoma S180 tumor cells stimulated robust antitumor immunity to autologous tumor cells in both syngenic and allogenic mice. The antitumor activity requires both T and B cells, but not NK cells. When a mouse lung carcinoma (TC-1) whole tumor cell vaccine was combined with the S180 vaccine, the antitumor immunity against live TC-1 tumor cells is significantly enhanced compared to a TC-1 whole cell vaccine alone. This antitumor immunity not only prevents live tumor challenge but also eradicates existing tumor cells. A similar phenomenon was also observed when S180 vaccine was combined with LL2 Lewis lung carcinoma tumor cells. Therefore, S180 vaccine may serve as an adjuvant for other whole tumor cell vaccines.
Collapse
Affiliation(s)
- Jinhua Li
- Oncology Research Institute, Greenville Hospital System University Medical Center, Greenville, SC 29605, United States
| | | | | | | | | | | | | |
Collapse
|
8
|
Deorukhkar AA, Chander R, Pandey R, Sainis KB. A novel N-alkylated prodigiosin analogue induced death in tumour cell through apoptosis or necrosis depending upon the cell type. Cancer Chemother Pharmacol 2007; 61:355-63. [PMID: 17429627 DOI: 10.1007/s00280-007-0475-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2006] [Accepted: 03/16/2007] [Indexed: 01/28/2023]
Abstract
PURPOSE To investigate the mechanism of cell death induced by the N-alkylated prodigiosin analogue, 2,2'-[3-methoxy-1'amyl-5'-methyl-4-(1''-pyrryl)] dipyrryl-methene (MAMPDM) in S-180 and EL-4 tumour cell lines. METHODS Effect of MAMPDM on cell viability was assessed by MTT dye conversion. Induction of apoptosis was assessed by monitoring caspase 3 activity using a fluorogenic substrate, fragmentation of DNA by gel electrophoresis and sub-diploid DNA containing cells by flowcytometry. Necrosis was estimated by flowcytometric analysis of the uptake of propidium iodide. RESULTS MAMPDM inhibited the proliferation of murine fibrosarcoma, S-180 cells and induced cell death. Investigations into the mechanism of cell death by MAMPDM in S-180 cells showed absence of hallmarks of apoptotic cell death such as activation of caspase 3, DNA fragmentation and presence of cells with sub-diploid DNA content. However, there was a rapid loss of membrane integrity as assessed by uptake of propidium iodide, which is characteristic of necrosis. In contrast to induction of necrosis in S-180 cells, MAMPDM induced apoptotic cell death in EL-4 cells as evident by activation of caspase 3, fragmentation of DNA and sub-diploid DNA containing cells. CONCLUSIONS MAMPDM could induce cell death by either apoptosis or necrosis depending upon the cell type. This would be of advantage in elimination of tumor cells defective in apoptotic pathway and therefore, refractory to the conventional therapies.
Collapse
Affiliation(s)
- Amit A Deorukhkar
- Food Technology Division, Bhabha Atomic Research Centre, Mumbai 400 085, India
| | | | | | | |
Collapse
|
9
|
Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, Pettenati MJ, Sanders AM, Weir HM, Du W, Kim J, Simpson AJG, Old LJ, Cui Z. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A 2006; 103:7753-8. [PMID: 16682640 PMCID: PMC1458507 DOI: 10.1073/pnas.0602382103] [Citation(s) in RCA: 115] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Spontaneous regression/complete resistance (SR/CR) mice resist very high doses of cancer cells that are lethal to WT mice even at low doses. In this study, we show that this resistance is mediated by rapid infiltration of leukocytes, mostly of innate immunity, in both primary and repeated challenges. Formation of rosettes with infiltrating natural killer cells, neutrophils, and macrophages was required for the subsequent destruction of cancer cells through rapid cytolysis. Highly purified natural killer cells, macrophages, and neutrophils from the SR/CR mice independently killed cancer cells in vitro. The independent killing activity by each subset of effector cells is consistent with the observation that the resistance was abolished by depleting total infiltrating leukocytes but not by depleting only one or two subsets of leukocytes. The resistance was completely transferable to WT recipient mice through SR/CR splenocytes, bone marrow cells, or enriched peritoneal macrophages, either for prevention against subsequent cancer challenges or eradication of established malignancy at distant sites.
Collapse
Affiliation(s)
| | | | | | | | - C. Von Kap-Herr
- Department of Pediatrics, Section on Medical Genetics, Wake Forest University School of Medicine, Winston-Salem, NC 27157; and
| | - Mark J. Pettenati
- Department of Pediatrics, Section on Medical Genetics, Wake Forest University School of Medicine, Winston-Salem, NC 27157; and
| | | | | | - Wei Du
- Departments of *Pathology
| | | | | | - Lloyd J. Old
- Ludwig Institute for Cancer Research, New York, NY 10158
- To whom correspondence may be addressed. E-mail:
or
| | - Zheng Cui
- Departments of *Pathology
- To whom correspondence may be addressed. E-mail:
or
| |
Collapse
|
10
|
Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C, Vogelstein B, St. Croix B, Kinzler KW, Huso DL. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci U S A 2006; 103:3351-6. [PMID: 16492758 PMCID: PMC1413931 DOI: 10.1073/pnas.0511306103] [Citation(s) in RCA: 111] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Tumor endothelial marker 1 (Tem1; endosialin) is the prototypical member of a family of genes expressed in the stroma of tumors. To assess the functional role of Tem1, we disrupted the Tem1 gene in mice by targeted homologous recombination. Tem1(-/-) mice were healthy, their wound healing was normal, and tumors grew normally when implanted in s.c. sites. However, there was a striking reduction in tumor growth, invasiveness, and metastasis after transplantation of tumors to abdominal sites in mice without functional Tem1 genes. These data indicate that the stroma can control tumor aggressiveness and that this control varies with anatomic site. Therefore, they have significant implications for the mechanisms underlying tumor invasiveness and for models that evaluate this process.
Collapse
Affiliation(s)
- Akash Nanda
- *The Sidney Kimmel Comprehensive Cancer Center
- Ludwig Center for Cancer Genetics and Therapeutics
| | | | | | | | | | - Christine Gan
- *The Sidney Kimmel Comprehensive Cancer Center
- Ludwig Center for Cancer Genetics and Therapeutics
| | - Bert Vogelstein
- *The Sidney Kimmel Comprehensive Cancer Center
- Ludwig Center for Cancer Genetics and Therapeutics
- Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21205; and
- To whom correspondence may be addressed. E-mail:
, , or
| | - Brad St. Croix
- **Tumor Angiogenesis Section, Mouse Cancer Genetics Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702
| | - Kenneth W. Kinzler
- *The Sidney Kimmel Comprehensive Cancer Center
- Ludwig Center for Cancer Genetics and Therapeutics
- To whom correspondence may be addressed. E-mail:
, , or
| | - David L. Huso
- *The Sidney Kimmel Comprehensive Cancer Center
- Department of Comparative Medicine, and
- To whom correspondence may be addressed. E-mail:
, , or
| |
Collapse
|
11
|
Cui Z, Willingham MC, Hicks AM, Alexander-Miller MA, Howard TD, Hawkins GA, Miller MS, Weir HM, Du W, DeLong CJ. Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci U S A 2003; 100:6682-7. [PMID: 12724523 PMCID: PMC164507 DOI: 10.1073/pnas.1031601100] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
We have established and studied a colony of mice with a unique trait of host resistance to both ascites and solid cancers induced by transplantable cells. One dramatic manifestation of this trait is age-dependent spontaneous regression of advanced cancers. This powerful resistance segregates as a single-locus dominant trait, is independent of tumor burden, and is effective against cell lines from multiple types of cancer. During spontaneous regression or immediately after exposure, cancer cells provoke a massive infiltration of host leukocytes, which form aggregates and rosettes with tumor cells. The cytolytic destruction of cancer cells by innate leukocytes is rapid and specific without apparent damage to normal cells. The mice are healthy and cancer-free and have a normal life span. These observations suggest a previously unrecognized mechanism of immune surveillance, which may have potential for therapy or prevention of cancer.
Collapse
Affiliation(s)
- Zheng Cui
- Department of Pathology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Nava G, Ocadiz R, Ortega V, Alfaro G. Damage in B2m genes and DNA methylation of H-2 genes are involved in loss of expression of class I MHC products on the membrane of LR.4, a cell line derivative of the T-cell lymphoma L5178Y. EUROPEAN JOURNAL OF IMMUNOGENETICS : OFFICIAL JOURNAL OF THE BRITISH SOCIETY FOR HISTOCOMPATIBILITY AND IMMUNOGENETICS 1992; 19:141-58. [PMID: 1627535 DOI: 10.1111/j.1744-313x.1992.tb00053.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
We have isolated an H-2 deficient cell line (LR.4) from the T-cell lymphoma L5178Y which grew without restrictions in the peritoneal cavity of different inbred strains of mice. The use of polyclonal anti-H-2 antiserum and complement indicated that LR.4 cells did not express class I determinants on the cell membrane. Southern blots of genomic DNA of LR.4 cells showed that B2m genes were severely damaged and that class I H-2 genes were extensively methylated. Consequently, LR.4 cells failed to transcribe mRNAs for both B2m and class I H-2 genes. On the other hand, specific immunity to LR.4 was demonstrated in C57BL/6J mice since, in subsequent challenges with either LR.4 or EL4.4, LR.4 did not grow, whereas EL4.4 grew and killed the mice. In C57BL/6J mice, rejection of LR.4 was accompanied by the production of cytotoxic antibodies. The immune response induced in C57BL/6J mice was determined by non-H-2 antigenic determinants in LR.4 cells.
Collapse
Affiliation(s)
- G Nava
- Departamento de Inmunologia, Universidad Nacional Autonoma de Mexico
| | | | | | | |
Collapse
|